Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Versant Venture Management, LLC
Form 13F · Q2 2026

Versant Venture Management, LLC

CIK 1560009Filed 2026-08-1213F-HR View the filing on EDGAR ↗
$163M
Reported book value
8
Positions
12
Quarters on record
Top 50
Positions

Versant Venture Management, LLC — holdings

Top 8 positions of 8, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1GLUE Monte Rosa Therapeutics Inc3.2M+0.0%$77M47.3%
2IPSC Century Therapeutics Inc12.2M+0.0%$30M18.3%
3JBIO Jade Biosciences Inc991,783−35.0%$22M13.6%
4LENZ Lenz Therapeutics Inc2.7M+0.0%$15M9.3%
5CTNM Contineum Therapeutics Inc542,628+0.0%$9M5.5%
6CRSP Crispr Therapeutics Ag148,831+0.0%$8M5.0%
7SKYE Skye Bioscience Inc2.0M+0.0%$1M0.9%
8TPST Tempest Therapeutics, Inc.269,772+0.0%$299,4470.2%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.